Alnylam Pharmaceuticals Inc (NAS:ALNY)
$ 265.9 -3.05 (-1.13%) Market Cap: 34.30 Bil Enterprise Value: 33.17 Bil PE Ratio: 0 PB Ratio: 1,063.60 GF Score: 78/100

Alnylam Pharmaceuticals Inc at JPMorgan Healthcare Conference (Virtual) Transcript

Jan 10, 2022 / 02:45PM GMT
Release Date Price: $150.16 (+1.37%)
Anupam Rama
JPMorgan Chase & Co, Research Division - VP and Analyst

All right. We'll get started. Welcome, everyone, to the 40th Annual JPMorgan Healthcare Conference. My name is Anupam Rama. I'm one of the senior biotech analysts here at JPMorgan. I'm joined by Priyanka Grover, Malcolm Kuno and Caleb Smith from the team.

Our next presenting company is Alnylam and presenting on behalf of the company, we have CEO, Yvonne Greenstreet. I want to remind all the attendees that there's an ask a question feature in the portal. And if you put a question in there, I'm happy to ask on your behalf during the session.

With that, Yvonne, if you want to take the way.

Yvonne L. Greenstreet
Alnylam Pharmaceuticals, Inc. - CEO & Director

Thanks, Anupam. Look, it really is an honor to be speaking to all of you today in my first public presentation as Alnylam CEO, and I couldn't be more excited about Alnylam prospects.

Let's move to Slide 2. During my remarks this morning, I will be making some forward-looking statements.

Next

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot